Decreased 5-hydroxymethylcytosine levels are associated with TET2 mutation and unfavorable overall survival in myelodysplastic syndromes

References

• Tefferi A, Vardiman JW. Myelodysplastic syndromes. N Engl J Med 2009;361:1872–1885.
   PubMed Web of Science ®Google Scholar
• Walter MJ, Ding L, Shen D, et al. Recurrent DNMT3A mutations in patients with myelodysplastic syndromes. Leukemia 2001;25:1153–1158.
   Web of Science ®Google Scholar
• Nikoloski G, Langemeijer SM, Kuiper RP, et al. Somatic mutations of the histone methyltransferase gene EZH2 in myelodysplastic syndromes. Nat Genet 2010;42:665–667.
   PubMed Web of Science ®Google Scholar
• Pardanani A, Patnaik MM, Lasho TL, et al. Recurrent IDH mutations in high-risk myelodysplastic syndrome or acute myeloid leukemia with isolated del(5q). Leukemia 2010;24:1370–1372.
   PubMed Web of Science ®Google Scholar
• Delhommeau F, Dupont S, Della Valle V, et al. Mutation in TET2 in myeloid cancers. N Engl J Med 2009;360:2289–2301.
   PubMed Web of Science ®Google Scholar
• Langemeijer SM, Kuiper RP, Berends M, et al. Acquired mutations in TET2 are common in myelodysplastic syndromes. Nat Genet 2009;41:838–842.
   PubMed Web of Science ®Google Scholar
• Tefferi A, Lim KH, Abdel-Wahab O, et al. Detection of mutant TET2 in myeloid malignancies other than myeloproliferative neoplasms: CMML, MDS, MDS/MPN and AML. Leukemia 2009;23:1343–1345.
   PubMed Web of Science ®Google Scholar
• Figueroa ME, Skrabanek L, Li Y, et al. MDS and secondary AML display unique patterns and abundance of aberrant DNA methylation. Blood 2009;114:3448–3458.
   PubMed Web of Science ®Google Scholar
• Tahiliani M, Koh KP, Shen Y, et al. Conversion of 5-methylcytosine to 5-hydroxymethylcytosine in mammalian DNA by MLL partner TET1. Science 2009;324:930–935.
   PubMed Web of Science ®Google Scholar
• Brunning RD, Orazi A, Germing U, et al. Myelodysplastic syndroms/neoplasms, overview. In:Swerdlow SH, Campo E, Harris NL, et al editors. WHO classification of haematopoietic and lymphoid tissues. Lyon: IARC; 2008. pp 88–93.
   Google Scholar
• Greenberg P, Tuechler H, Schanz J, et al. Revised international prognostic scoring system for myelodysplastic syndromes. Blood 2012;120:2454–2465.
   PubMed Web of Science ®Google Scholar
• Den Dunnen JT, Antonarakis SE. Nomenclature for the description of human sequence variations. Hum Genet 2002;109:121–124.
   Web of Science ®Google Scholar
• Herman JG, Graff JR, Myohanen S, et al. Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci USA 1996;93:9821–9826.
   PubMed Web of Science ®Google Scholar
• Mohr F, Dohner K, Buske C, et al. TET genes: new players in DNA demethylation and important determinants for stemness. Exp Hematol 2011;39:272–281.
   PubMed Web of Science ®Google Scholar
• Jankowska AM, Szpurka H, Tiu RV, et al. Loss of heterozygosity 4q24 and TET2 mutations associated with myelodysplastic/myeloproliferative neoplasms. Blood 2009;113:6403–6410.
   PubMed Web of Science ®Google Scholar
• Figueroa ME, Abdel-Wahab O, Lu C, et al. Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. Cancer Cell 2010;18:553–567.
   PubMed Web of Science ®Google Scholar
• Thol F, Weissinger EM, Krauter J, et al. IDH1 mutations in patients with myelodysplastic syndromes are associated with an unfavorable prognosis. Haematologica 2010;95:1668–1674.
   PubMed Web of Science ®Google Scholar
• Ko M, Huang Y, Jankowska AM, et al. Impaired hydroxylation of 5-methylcytosine in myeloid cancers with mutant TET2. Nature 2010;468:839–843.
   PubMed Web of Science ®Google Scholar
• Konstandin N, Bultmann S, Szwagierczak A, et al. Genomic 5-hydroxymethylcytosine levels correlate with TET2 mutations and a distinct global gene expression pattern in secondary acute myeloid leukemia. Leukemia 2011;25:1649–1652.
   PubMed Web of Science ®Google Scholar
• Esteller M. Epigenetics in cancer. N Engl J Med 2008;358: 1148–1159.
   PubMed Web of Science ®Google Scholar
• Gal-Yam EN, Saito Y, Egger G, et al. Cancer epigenetics: modifications, screening and therapy. Annu Rev Med 2008;59:267–280.
   PubMed Web of Science ®Google Scholar
• Robertson KD, Jones PA. DNA methylation: past, present and future directions. Carcinogenesis 2000;21:461–467.
   PubMed Web of Science ®Google Scholar
• Quesnel B, Guillerm G, Vereecque R, et al. Methylation of the p15(INK4b) gene in myelodysplastic syndromes is frequent and acquired during disease progression. Blood 1998;91:2985–2990.
   PubMed Web of Science ®Google Scholar
• Shen L, Kantarjian H, Guo Y, et al. DNA methylation predicts survival and response to therapy in patients with myelodysplastic syndromes. J Clin Oncol 2010;28:605–613.
   PubMed Web of Science ®Google Scholar
• Bestor TH. The DNA methyltransferases of mammals. Hum Mol Genet 2000;9:2395–2402.
   PubMed Web of Science ®Google Scholar
• Aoki E, Ohashi H, Uchida T, et al. Expression levels of DNA methyltransferase genes do not correlate with p15IN K4B gene methylation in myelodysplastic syndromes. Leukemia 2003;17: 1903–1904.
   PubMed Web of Science ®Google Scholar